News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Stablecoin rails slow 19%, but dollar tokens quietly keep compounding
Crypto.News·2026/04/28 16:06
Huge 400x Opportunity: BlockDAG’s Casino Launch on May 7th Has Crypto Investors Ditching Solana and Stellar
BlockchainReporter·2026/04/28 16:03
XRP Records 200-Week Average Breach, Opening the Path to a 47% Technical Drawdown
CryptoNewsNet·2026/04/28 16:01
Dogecoin Open Interest Jumps 33% in 5 Days, Analyst Opens Massive Short
CryptoNewsNet·2026/04/28 16:01
XRP Endgame Theory: Analyst Reveals How XRP Price May Climb in a Utility-Driven Cycle
CryptoNewsNet·2026/04/28 16:01
Dogecoin Futures Activity Spikes Amid 33% OI Surge
CryptoNewsNet·2026/04/28 16:01
Amboss launches RailsX for self-custodial bitcoin and stablecoin trading on Lightning
The Block·2026/04/28 16:01
RWA yield platform Nuva, co-incubated by Animoca, raises $5.2 million in seed funding
The Block·2026/04/28 15:57
From treasuries to validators: Sharplink doubles down on Ethereum staking
Crypto.News·2026/04/28 15:54
XRP Price Flat Despite Strongest ETF Inflows of 2026
CryptoNewsNet·2026/04/28 15:48
Flash
12:38
Cannae Holdings, Inc. has successfully completed the full acquisition of Exeter Rugby Group, significantly advancing the company's strategic shift to focus its investments on sports and entertainment assets.By acquiring full ownership of the rugby club, Cannae Holdings further consolidates its presence in the sector, aiming to identify and integrate high-value entertainment assets. This strategic acquisition not only expands the company's asset portfolio but also positions it more advantageously in the rapidly evolving sports entertainment market.
12:38
Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 "Miracle" clinical trial, showing positive data.The results show that the core candidate drug Annamycin demonstrated significantly superior efficacy in inducing complete remission compared to the control group, with the complete remission rate reaching three times that of the control group. This positive data provides strong momentum for the further development of Annamycin in the treatment of acute myeloid leukemia. The success of the interim analysis indicates that the drug has made breakthrough progress in key efficacy indicators, and it is expected to offer new treatment options for patients. The company will continue to advance clinical trials to obtain more confirmatory data.
12:37
U.S. Stock Index Futures Turn Lower On June 30, Dow Jones futures fell by 0.11%, S&P 500 futures declined by 0.07%, and Nasdaq 100 futures decreased by 0.05%.